A Plasma-Derived Von Willebrand Factor/Factor VIII Concentrate (Wilate)

被引：0
|
作者：
不详
机构：
来源：
MEDICAL LETTER ON DRUGS AND THERAPEUTICS | 2010年 / 52卷 / 1340期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：46 / 47
页数：2
相关论文
共 50 条
  • [41] First results of a long-term pharmacovigilance with plasma derived von-Willebrand- factor/Factor VIII concentrate
    Krause, M.
    Varvenne, M.
    Zotz, R. B.
    Niekrens, C.
    Scholz, U.
    Gerhardt, A.
    Kemkes-Matthes, B.
    Krammer-Steiner, B.
    Stockschlaeder, M.
    Zacharias, C.
    Auerswald, G.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 : 449 - 449
  • [42] Efficacy and Safety of Prophylaxis with a Plasma-Derived Von Willebrand Factor/Factor VIII Concentrate in Children and Adolescents with Von Willebrand Disease - a Sub-Analysis of Data from the Wil-31 Study
    Robert, F. Sidonio, Jr.
    Dubey, Leonid
    Vilchevska, Kateryna V.
    Inati, Adlette
    Khayat, Claudia Djambas
    BLOOD, 2023, 142
  • [43] Efficacy and safety evaluation of Fanhdi(R), a plasma-derived factor VIII/von Willebrand factor concentrate, in Von Willebrand's disease patients undergoing surgery or invasive procedures: A prospective clinical study
    Jimenez-Yuste, Victor
    Nunez, Laura
    Alvarez-Roman, Maria Teresa
    Martin-Salces, Monica
    Haya, Saturnino
    Federici, Augusto B.
    Grifols, Carlota
    Mairal, Esther
    Torres, Mireia
    Paez, Antonio
    HAEMOPHILIA, 2022, 28 (01) : E23 - E27
  • [44] REAL-WORLD EFFICACY AND SAFETY OF PLASMA-DERIVED VON WILLEBRAND FACTOR-CONTAINING FACTOR VIII CONCENTRATES IN PATIENTS WITH VON WILLEBRAND DISEASE IN ITALY
    Federici, A. B.
    Mairal, E.
    HAEMOPHILIA, 2023, 29 : 145 - 146
  • [45] Real-World Efficacy and Safety of Plasma-Derived Von Willebrand Factor-Containing Factor VIII Concentrates in Patients With Von Willebrand Disease in Italy
    Federici, Augusto B.
    Santoro, Rita Carlotta
    Santoro, Cristina
    Pieri, Lisa
    Santi, Roberto Mario
    Barillari, Giovanni
    Borchiellini, Alessandra
    Tosetto, Alberto
    Zanon, Ezio
    De Cristofaro, Raimondo
    Mairal, Esther
    Mir, Roser
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2024, 30
  • [46] A Case Series Evaluating the Use of a Von Willebrand Factor/Factor VIII Concentrate (Wilate r) for Immune Tolerance Induction (ITI) in Children with Severe Factor VIII Deficiency
    Belletrutti, Mark J.
    Seiferman-Nelson, Roxanne
    Granfield, Bonny
    BLOOD, 2014, 124 (21)
  • [47] EFFECT OF VON WILLEBRAND FACTOR ON THE ASSAY OF FACTOR-VIII CONCENTRATE
    MIURA, Y
    THROMBOSIS AND HAEMOSTASIS, 1991, 65 (06) : 1318 - 1318
  • [48] Recombinant von Willebrand factor for perioperative bleeding management in pediatric patient with allergy to plasma-derived von Willebrand factor
    Tran, Thuy B.
    Arnall, Justin R.
    Kleiboer, Brendan
    Hinson, Ashley
    PEDIATRIC BLOOD & CANCER, 2023, 70 (02)
  • [49] Ex vivo evaluation of the effect of plasma-derived factor VIII/von Willebrand factor in patients with severe hemophilia A on emicizumab prophylaxis
    Raventos, Aida
    Arias-Salgado, Elena G.
    Perez, Alba
    Alvarez-Roman, Maria Teresa
    Butta, Nora V.
    Monzon Manzano, Elena
    Acuna, Paula
    Jimenez-Yuste, Victor
    Costa, Montserrat
    Bravo, Maria Isabel
    CLINICAL AND EXPERIMENTAL MEDICINE, 2024, 25 (01)
  • [50] Managing von Willebrand disease with inhibitors during prophylaxis with a plasma derived von Willebrand factor/factor VIII concentrate-the WIL-31 study
    Khayat, C. D.
    Sidonio, R. F.
    Pavlova, A.
    HAEMOPHILIA, 2024, 30 : 131 - 131
12345